Search in the Abstract Database

Search Abstracts 2011

* = Presenting author

P304. Normalization of health-related quality of life in inflammatory bowel disease patients in long remission with anti-TNFα treatment

V. Robles1, N. Borruel1, E. López1, R. González2, I. Castells1, A. Torrejón1, F. Casellas1

1Hospital Universitario Valle de Hebrón, Barcelona, Spain; 2Hospital de Cruces, Bilbao, Spain

Aim: Inflammatory bowel disease (IBD) provoques a strong impact in the quality of life of people who suffer from it, with an impairment of its health-related quality of life (HRQOL). One of the purposes of the treatment, if not definitive healing, should be restoring patient's health perception. We have a threshold in IBDQ-36 questionaire, which correlates to normal general population. Reaching this puntuation let us to know if a treatment restores or not the HRQOL. Our aim is to determine if patients in long remission induced with biologic agents recover HRQOL.

Material and Methods: We identify a group of IBD patients in clinical remission (CAI < 6 or Harvey-Brandshaw <3) for one year with infliximab or adalimumab treatment. Patients completed a IBDQ-36 questionnaire. We consider a HRQOL normalization when the global puntuation reaches 209 points (Huamán JW, Casellas F, Borruel N, et al. JCC in press).

Results: We included a group of 29 patients (29 females, and 5 males), 3 with ulcerative colitis and 26 with Crohn's disease. The mean reactive C protein was 0.48 (IC 95%, 0.24–0.72). The 86% (n = 25) followed a combinated treatment, with biologic and immunomodulatory regimen. A total of 21 patients (72%) had a global IBDQ-36 puntuation higher than 209 points.

Conclusion: Patients in long remission with antiTNFα treatment get a normalization health-related quality of life.